Trial Profile
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2021
Price :
$35
*
At a glance
- Drugs Brilaroxazine (Primary) ; Aripiprazole
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms REFRESH
- Sponsors Reviva Pharmaceuticals
- 26 Apr 2021 Results (full details) presented in a Reviva pharmaceuticals media release.
- 22 Mar 2021 Primary endpoint of Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score has been met, according to a Reviva Pharmaceuticals media release.
- 04 Apr 2018 Results assessing population pharmacokinetic under non steady-state and steady-state (n=175) published in the European Journal of Drug Metabolism and Pharmacokinetics.